# Ipamorelin Benefits Reported in Research > Ipamorelin benefits reported in research: GH pulses, bone growth, weight protection in wasting, and the reported sleep and recovery effects. Cited evidence, labeled plainly. What the studies actually demonstrate — separated cleanly from what the research-use community reports anecdotally. ## Before you read on The ipamorelin benefits worth taking seriously fall into two buckets, and this page keeps them apart. Bucket one is what studies measured: a clean pulse of growth hormone without much cortisol [1], dose-dependent bone growth in rats [4], and protection against weight loss in a chemotherapy model [5]. Bucket two is what people report but no trial has confirmed: deeper sleep, faster recovery, and a slow leaner look (anecdotal). The single human efficacy trial did not show the benefit it tested for [3]. So the strongest, best-documented benefits are mechanistic and preclinical; the popular lifestyle benefits are real-world reports, not proof. Both are laid out below, clearly labeled. ## Demonstrated in studies: a clean growth-hormone pulse The single best-documented benefit is pharmacological: ipamorelin releases growth hormone potently and selectively. In its founding characterization it matched the older peptide GHRP-6 for GH release (swine ED50 2.3 vs 3.9 nmol/kg) but, unlike GHRP-6, did not raise ACTH or cortisol even at more than 200-fold its GH ED50 [1]. In healthy men, that translates to a single clean GH pulse peaking near 40 minutes after an IV dose [2]. The benefit here is specificity — a GH signal with minimal stress-hormone or prolactin spillover. What that clean pulse delivers in terms of human body composition has not been measured in a controlled trial. ## Demonstrated in animals: bone, weight protection, and recovery context In rats, subcutaneous ipamorelin over 15 days raised longitudinal bone growth rate dose-dependently from 42 to 52 microm/day — and notably did so without changing systemic IGF-1 [4]. In a 2024 ferret model of chemotherapy-induced wasting, it cut body-weight loss by about 24% through a peripheral mechanism [5]. A 2026 orthopaedic narrative review reported that CJC-1295 + ipamorelin improved maximal tetanic tension in a mouse model of glucocorticoid-induced muscle loss, while stressing the evidence is limited to animals [15]. The throughline: real, measurable effects on bone and on weight in catabolic states — all preclinical, none yet replicated in a human outcome trial. ## Reported by users, not proven: sleep, recovery, and leanness Beyond the studies, the research-use community consistently reports a recognizable cluster of benefits — **anecdotal, not clinical evidence**. The most-cited is deeper, more restorative sleep, often within a week or two, sometimes with vivid dreams early on. Many also describe faster recovery between training sessions and less muscle soreness. A smaller group reports a gradual leaner appearance over weeks to months, though that is heavily confounded by concurrent diet and training. None of these come from a controlled trial, and none should be read as a proven outcome. The full set of reported effects, including the downsides, is on the [Ipamorelin effects](/effects) page, and the underlying studies are on the [Ipamorelin research](/research) page. ## The honest ceiling on the benefit claims Every benefit above sits under one hard limit: there is no completed human trial showing ipamorelin improves body composition, athletic performance, or aging outcomes. The one published Phase 2 RCT, for postoperative ileus, missed its primary endpoint [3]. Recent reviews place ipamorelin firmly in the investigational column and emphasize the absence of rigorous human evidence [16][18]. The benefits worth stating plainly are mechanistic and preclinical; the lifestyle benefits are reported, not demonstrated. This digest reports both and conflates neither. --- A data desk reading of the ipamorelin literature — every number pinned to its study, nothing here dosed, prescribed, compounded, or sold.